Oxigene announces positive data from phase 2 trials of CA4P for thyroid cancer

New York, June 5 - Oxigene, Inc. reported positive data from two phase 2 clinical trials suggesting the therapeutic potential of its lead therapeutic compound under development, CA4P, in the treatment of anaplastic thyroid cancer.

The separate trials show patient response, as well as the biological activity of CA4P when CA4P is used either in combination with chemotherapy or as a monotherapy.

The first clinical trial from which data was released is an open-label, phase 2 clinical trial of CA4P for the treatment of imageable solid tumors and is being conducted in the United States under Oxigene's Investigational New Drug application on file with the Food and Drug Administration.

The trial is to evaluate the safety and anti-cancer activity of CA4P-carboplatin-paclitaxel therapy.

The trial enrolled individuals with various cancer types, of which two had anaplastic thyroid cancer.

Treatment with CA4P in combination with chemotherapy resulted in stabilized disease in one anaplastic thyroid cancer patient and a partial response (greater than 50% tumor reduction) in the second patient.

Further, analysis of blood flow volume to the tumors showed a statistically significant and sizeable reduction of more than 73% for both patients.

Oxigene anticipates that the complete data for this trial will be released by the end of the year.

A second trial showed the biological activity of CA4P, supporting the potential therapeutic benefit that could be gained from CA4P in combination with chemotherapy in this indication.

The phase 2 study of Combretastatin A4 Phosphate in patients with advanced anaplastic thyroid carcinoma has enrolled 21 patients to date.

From this group, 29% experienced progression-free survival greater than three months (survival for patients who benefited ranged from 12 weeks to 84+ weeks). Investigators noted that two patients remain on therapy. One of these individuals appeared to show a dramatic clinical benefit after two cycles of CA4P, with near partial response of metastatic lung lesions significantly decreasing in size or eliminated completely as confirmed by CT scan.

Investigators reported that CA4P therapy was well tolerated with no clinically meaningful myelosuppression or cardiac toxicity observed.

Located in Waltham, Mass., Oxigene is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.